MedTrace Logo

Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen

NCT05731258 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-02-16

No results posted yet for this study

Summary

The goal of this observational study aims to observe and evaluate the efficacy and safety of a liposomal doxorubicin containing regimen in the postoperative adjuvant treatment of breast cancer patients.

Conditions

  • Breast Cancer
  • Liposomal Doxorubicin
  • Efficacy
  • Safety
  • Postoperative Adjuvant Treatment

Interventions

DRUG

Liposomal doxorubicin containing regimen

Liposomal doxorubicin hydrochloride (PLD) 30-40mg/m2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2027-10-31
Completion
2032-10-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05731258 on ClinicalTrials.gov